DOC Healthpeak Properties
- 19.150
- -0.050-0.26%
- 19.120
- -0.030-0.16%
Healthpeak Properties News
Healthpeak Properties Announces Joint Venture Wind-Down
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak") and King Street Properties ("KSP") today announced that Healthpeak has acquired KSP's minority interest in the joint ven
BMO Capital Adjusts Price Target on Healthpeak Properties to $23 From $21, Keeps Outperform Rating
Healthpeak Properties (DOC) has an average rating of outperform and price targets ranging from $18 to $30.50, according to analysts polled by Capital IQ. Price: 18.99, Change: +0.02, Percent Change: +
Real Estate Stocks Outperform Major Market Averages as Rate Hikes Are Ruled Out, Earnings Continue to Grow
Real estate stocks outperformed major market averages as the Federal Reserve ruled out a near-term rate hike despite the inflation data, and the sector continued to demonstrate solid balance sheets and earnings.
Wedbush Upgrades Healthpeak Properties to Outperform
Wedbush analyst Richard Anderson upgrades Healthpeak Properties (NYSE:DOC) from Neutral to Outperform.
Healthpeak Properties Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 — Wedbush Upgrades Neutral → Outperform 04/22/2024 14.94% Mizuho → $22 Reinstates → Buy 04/10/
Healthpeak Properties, Inc. (NYSE:DOC) Q1 2024 Earnings Call Transcript
Form 144 | Healthpeak Properties(DOC.US) Insider Proposes to Sell 172.51K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 29, $Healthpeak Properties(DOC.US)$ Insider GARVEY CHRISTINE intends to sell 9,200 shares of its common stock on Apr 29, with a total market value of approximately $172.51K
Real Estate Stocks Finish in Green as Analysts Turn Positive, Earnings Surprise to Upside
Real estate stocks ended the week in green after three consecutive weeks of decline, as analysts turned positive as well as the sector delivered strong earnings, even amid dim chances of a near-term rate cut.
Healthpeak Properties Inc (DOC) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...
Decoding Healthpeak Properties Inc (DOC): A Strategic SWOT Insight
Earnings Call Summary | Healthpeak Properties(DOC.US) Q1 2024 Earnings Conference
The following is a summary of the Healthpeak Properties, Inc. (DOC) Q1 2024 Earnings Call Transcript:Financial Performance:Healthpeak Properties increased its 2024 earnings guidance by $0.02 at the mi
Healthpeak Properties Board Changes and Shareholder Votes
BNP Paribas Adjusts Price Target on Healthpeak Properties to $21 From $19
Healthpeak Properties (DOC) has an average outperform rating and price target range of $18 to $30.50, according to analysts polled by Capital IQ. Price: 18.77, Change: +0.43, Percent Change: +2.32
Research Alert: CFRA Maintains Buy Opinion On Shares Of Healthpeak Properties, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target by $2 to $23 on a for
Healthpeak Properties Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY24 Guidance.
Healthpeak Properties Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY24 Guidance.
Healthpeak Properties To Go Ex-Dividend On May 3rd, 2024 With 0.3 USD Dividend Per Share
April 26th - $Healthpeak Properties(DOC.US)$ is trading ex-dividend on May 3rd, 2024. Shareholders of record on May 6th, 2024 will receive 0.3 USD dividend per share on May 17th, 2024. The ex-divi
Healthpeak Properties Earnings Missed, Revenue Topped Estimates
Buy Rating Affirmed for Healthpeak Properties Amid Strong Q1 Performance and Raised Financial Guidance
Healthpeak (DOC) Q1 FFO and Revenues Surpass Estimates
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.45 per share, beating the Zacks Consensus Estimate of $0.44 per share.
Healthpeak Properties Inc (DOC) Q1 2024 Earnings: Modest Gains Amid Strategic Expansions
Analysis
Price Target
No Data
